Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells

• Asıl Yazarlar: Min Ye (Yazar), Wei Huang (Yazar), Rui Liu (Yazar), Yingli Kong (Yazar), Yang Liu (Yazar), Xiaole Chen (Yazar), Jianhua Xu (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2021-07-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Lapatinib is an FDA-approved EGFR and HER2 tyrosine kinase inhibitor for the treatment of HER2-positive breast cancer patients. However, its therapeutic efficacy is limited by primary or acquired resistance. In the present study, we established breast cancers cells with acquired lapatinib resistance...